Rafael (NYSE:RFL - Get Free Report) was upgraded by research analysts at Wall Street Zen to a "hold" rating in a research report issued on Saturday.
Rafael Stock Performance
Shares of RFL stock opened at $2.09 on Friday. The firm has a market cap of $73.37 million, a P/E ratio of -2.22 and a beta of 0.97. The business's 50 day moving average price is $1.66 and its 200-day moving average price is $1.80. Rafael has a fifty-two week low of $1.28 and a fifty-two week high of $3.19.
Rafael (NYSE:RFL - Get Free Report) last announced its earnings results on Wednesday, June 11th. The company reported ($0.19) earnings per share for the quarter. The company had revenue of $0.36 million for the quarter. Rafael had a negative net margin of 3,127.60% and a negative return on equity of 24.75%.
Insiders Place Their Bets
In other news, CEO Howard S. Jonas purchased 13,080,457 shares of the company's stock in a transaction that occurred on Thursday, June 5th. The shares were bought at an average cost of $1.28 per share, for a total transaction of $16,742,984.96. Following the completion of the transaction, the chief executive officer directly owned 12,299,207 shares of the company's stock, valued at $15,742,984.96. This trade represents a -1,674.30% increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 10.20% of the company's stock.
Institutional Trading of Rafael
A number of hedge funds have recently modified their holdings of RFL. Ieq Capital LLC bought a new stake in Rafael during the first quarter worth about $447,000. Geode Capital Management LLC boosted its position in shares of Rafael by 17.9% in the 4th quarter. Geode Capital Management LLC now owns 174,561 shares of the company's stock worth $288,000 after purchasing an additional 26,493 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC bought a new stake in shares of Rafael in the 1st quarter worth approximately $26,000. Institutional investors own 11.30% of the company's stock.
About Rafael
(
Get Free Report)
Rafael Holdings, Inc primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in two segments, Healthcare and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Rafael, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rafael wasn't on the list.
While Rafael currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
